Press "Enter" to skip to content
HitGen and BioAge Shared their progress in the DNA-Encoded Library

HitGen and BioAge Shared their progress in the DNA-Encoded Library

By Willie Wise on April 7, 2021

Shanghai-based Stock Exchange-listed biotech company HitGen Inc. which is known for DNA Encoded Library screening announced important research progress in a collaboration with BioAge Labs, Inc. BioAge is a private biotechnology company developing small molecules for the treatment of diseases of ageing.

Both the companies collaborated and conducted research to identify and develop novel small-molecule compounds against a high value. It is a challenging biological target that is a critical component of the immune system. Dysregulation of this target is closely related to the cause of severe diseases in elderly humans, such as Alzheimer’s and cardiovascular disease.The availability of over 1 trillion small molecules generated by technology and the efficiency of the screening process has made it possible for HitGen to enable drug discovery projects for many organisations around the world.

The collaboration agreement stated that the Shanghai-based company has applied its DNA encoded library technology and discovered program compounds that met certain criteria. BioAge has received an exclusive license to these compounds as well as associated IP for further development and commercialization. HitGen will be eligible for milestone payments and sublicensing income from BioAge as the project progresses, in addition to research payments and an upfront license fee already paid.

Kristen Fortney, PhD, BioAge’s Chief Executive Officer said that the company is pleased to collaborate with HitGen to find novel small molecules against drug targets identified by BioAge’s platform, which analyzes samples collected over the lifespan to map the molecular pathways that drive human ageing. The HitGen’s DNA Encoded Library technology allows BioAge to discover novel, patentable molecules that modulate key ageing pathways.

Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen shared that the company is delighted to see the successful identification of novel compounds for this important biological target that BioAge has been pursuing. The progress is made by the close interaction and collaboration of the scientists from the two companies.

Published in Biotechnology and News

Willie Wise

Backed by a strong educational background with a degree in Biotechnology, Greenville Technical College, Willie D. Wise is an asset to The Healthcare News and is rightfully placed as the Chief Editor, owing to his vast experience in technical writing, marketing, and strategic planning. To hone his job skills in journalism, Wise has also completed a degree course in journalism from the University of South Carolina-Columbia. He is highly skilled with the art of news presentation and is adept in an editorial role with excellent time management and leadership qualities at his disposal. He ensures the best delivery from his team of writers and ensures excellent performance by his team. Besides his current job as the editor-in-chief at The Healthcare News, he is a regular writer for the biotechnology category. Given his intense interest in the field, his core career centers around writing which he does with complete dexterity. As a writer, he ensures appropriate title selection besides developing authentic, market-relevant content ideal for business discretion and also to suit promotional and marketing strategies of TheHealthcareNews. His writing style not only remains informative but also is high on lucidity to entice reader focus for longer. Crude facts and statistical details are also presented simplistically to connect with readers' grasping capabilities.

More from BiotechnologyMore posts in Biotechnology »
More from NewsMore posts in News »

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *